Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites
This study compared the pharmacokinetic profile and glucodynamic response of URLi when administered subcutaneously into the abdomen, upper arm, or thigh. An intravenous (IV) bolus administration was included to determine the absolute bioavailability at each injection site.METHODS: In this Phase I, randomized, open-label, 4-period, crossover study, healthy subjects received a single dose of 15 U URLi subcutaneously into the abdomen, upper arm, or thigh, or by intravenous injection. Serum insulin lispro concentrations and glucodynamic response during a 10-hour euglycemic clamp procedure were assessed after URLi administratio...
Source: Clinical Therapeutics - May 16, 2022 Category: Drugs & Pharmacology Authors: Jennifer K Leohr Mary Anne Dellva Elizabeth LaBell David E Coutant Helle Linnebjerg Source Type: research
A Case of Possible Levetiracetam Induced Aseptic Meningitis vs Viral Meningitis
DISCUSSION: In 2018, McDonald et al documented the first case of probable levetiracetam-related antiepileptic induced meningitis (AEIM). The mainstay of treatment is discontinuing the offending agent. Resolution of symptoms is typically 2 to 3 days after drug discontinuation as seen in this patient case report. Symptomatic resolution within days of stopping the suspected offending drug has been observed in all reported cases of AEIM where 1 to 2 weeks is generally seen with viral meningitis. Applying the Naranjo Scale yields a score of 4, which indicates possible levetiracetam-induced meningitis in this adult patient. Prov...
Source: CNS Spectrums - April 28, 2022 Category: Neurology Authors: P Brittany Vickery J Kyle Roach Stephen Vickery Source Type: research
A Case of Possible Levetiracetam Induced Aseptic Meningitis vs Viral Meningitis
DISCUSSION: In 2018, McDonald et al documented the first case of probable levetiracetam-related antiepileptic induced meningitis (AEIM). The mainstay of treatment is discontinuing the offending agent. Resolution of symptoms is typically 2 to 3 days after drug discontinuation as seen in this patient case report. Symptomatic resolution within days of stopping the suspected offending drug has been observed in all reported cases of AEIM where 1 to 2 weeks is generally seen with viral meningitis. Applying the Naranjo Scale yields a score of 4, which indicates possible levetiracetam-induced meningitis in this adult patient. Prov...
Source: CNS Spectrums - April 28, 2022 Category: Neurology Authors: P Brittany Vickery J Kyle Roach Stephen Vickery Source Type: research
Profile of Patients with Diabetes Treated with Insulin Lispro 200 U/ml: A Real-World Study from Spain
ConclusionsPROFILE-IL200 described the profile of patients treated with IL200 in clinical practice in Spain. Patients were middle-aged, with poor glycemic control, high BMI and associated comorbidities, and received high doses of insulin at IL200 initiation. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 21, 2022 Category: Endocrinology Source Type: research
Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan ‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects
AbstractThis phase 1 study compared the pharmacokinetic (PK) and glucose pharmacodynamic (PD) characteristics of biosimilar SAR342434 insulin lispro and Japan-reference Humalog insulin lispro. This was a randomized, double-blind, 2-period, crossover study. Thirty-six healthy Japanese male subjects underwent a 10-hour euglycemic clamp following a single subcutaneous 0.3-U/kg dose of SAR342434 or Humalog. Insulin lispro concentration and blood glucose were measured, and the glucose infusion rate (GIR) was adjusted to maintain the target blood glucose level. Primary PK end points were maximum plasma insulin lispro concentrati...
Source: Clinical Pharmacology in Drug Development - February 15, 2022 Category: Drugs & Pharmacology Authors: Masanari Shiramoto,
Tatsuya Yoshihara,
Wolfgang Schmider,
Yoshinori Takahashi,
Irene Nowotny,
Miyuki Kajiwara,
Hideya Muto Tags: Original Article Source Type: research
POSB393 Profile of Patients with Type 1 or Type 2 Diabetes Treated with Insulin Lispro 100 Units/ML Junior Kwikpen in Routine Clinical Practice in Spain
This study describes sociodemographic, clinical, and treatment characteristics of patients with diabetes who initiated treatment with JrKwikPen in real world practice in Spain. (Source: Value in Health)
Source: Value in Health - January 1, 2022 Category: International Medicine & Public Health Authors: M Rubio, N Duque, E Artime, E Caveda, E Spaepen, S D íaz Cerezo, FJ Ampudia-Blasco Source Type: research
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus
ConclusionsTechnosphere Insulin has a considerably faster onset and shorter duration of action than LIS. Consequently, the overall effect of TI is smaller than that of LIS and unit-for-unit dose conversion is not appropriate.Clinical Trial RegistrationClinicalTrials.gov, NCT02470637; 12 June, 2015 (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 13, 2021 Category: Drugs & Pharmacology Source Type: research
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog ® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
ConclusionsAcross the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range.Clinical Trial RegistrationNCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017). (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 1, 2021 Category: Drugs & Pharmacology Source Type: research
Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?
Conclusion.Novel ultra-rapid-acting insulins provide additional bolus insulin options, and their quick onset of action provides additional dosing flexibility for people with diabetes. Given their comparable efficacy and safety compared to other quick-acting insulins, health care providers should engage in shared decision-making with patients and their caregivers regarding possible use of ultra-rapid-acting insulin, taking into account their preferences, individualized considerations, and insurance formulary coverage. These new insulin formulations may be a suitable option for people with diabetes who are not able to achiev...
Source: Clinical Diabetes - October 1, 2021 Category: Endocrinology Source Type: research
Case of subcutaneous insulin resistance syndrome treated with ultra ‐rapid insulin lispro
We reported a case of subcutaneous insulin resistance syndrome that achieved good glycemic control with ultra-rapid insulin lispro, novel insulin formulation. Although it has been reported that the combination of insulin lispro and heparin is effective for subcutaneous insulin resistance syndrome, it is suggested that ultra-rapid insulin lispro might provide good glycemic control without heparin. AbstractSubcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40-year-old woman with type...
Source: Journal of Diabetes Investigation - September 28, 2021 Category: Endocrinology Authors: Takahiro Ishii,
Akihiro Katayama,
Mihiro Sue,
Remi Kuribayashi,
Masafumi Tenta,
Yuichi Matsushita,
Masaya Takeda,
Izumi Iseda,
Satomi Tani,
Kazuyuki Hida Tags: Case Report Source Type: research
Satisfaction, Preference and Injection Habits of Switching to 200 Units/ml Insulin Lispro Pen from 100 Units/ml: A Patient Survey in Germany
ConclusionsSatisfaction and preference for IL200 was high in this sample of patients using IL200 for 3 –12 months. Reasons were consistent with IL200 features, explaining the better patient experience and potential resource saving transitioning from a disposable MTI-100 pen. (Source: Diabetes Therapy)
Source: Diabetes Therapy - September 20, 2021 Category: Endocrinology Source Type: research
A case of subcutaneous insulin resistance syndrome treated with ultra ‐rapid insulin lispro
AbstractSubcutaneous insulin resistance (SIR) syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40-year-old woman with type 2 diabetes mellitus who had been diagnosed with SIR syndrome since the age of 29 and had been persistently treated with continuous subcutaneous insulin infusion using a mixture of insulin lispro and heparin. The patient was switched from insulin lispro plus heparin to ultra-rapid insulin lispro (URLi); given that it contains treprostinil and citrate, it is expected to have similar effects a...
Source: Journal of Diabetes Investigation - September 12, 2021 Category: Endocrinology Authors: Takahiro Ishii,
Akihiro Katayama,
Mihiro Sue,
Remi Kuribayashi,
Masafumi Tenta,
Yuichi Matsushita,
Masaya Takeda,
Izumi Iseda,
Satomi Tani,
Kazuyuki Hida Tags: CASE REPORT Source Type: research
